Mesenchymal stem cell therapies - Cytopeutics

Drug Profile

Mesenchymal stem cell therapies - Cytopeutics

Alternative Names: Autologous mesenchymal stem cell therapies

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytopeutics
  • Developer Cytopeutics; National University of Malaysia
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cartilage replacements; Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dilated cardiomyopathy

Most Recent Events

  • 05 Sep 2017 Discontinued - Phase-II for Dilated cardiomyopathy in Malaysia (Intracoronary)
  • 01 Jul 2014 No recent reports on development identified - Phase-II for Dilated cardiomyopathy in Malaysia (Intracoronary)
  • 01 Jul 2012 Phase-II clinical trials in Dilated cardiomyopathy in Malaysia (Intracoronary) (NCT01720888)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top